Profile data is unavailable for this security.
About the company
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
- Revenue in SEK (TTM)0.00
- Net income in SEK-179.67m
- Incorporated2003
- Employees26.00
- LocationXSpray Pharma AB (publ)Rasundavagen 12SOLNA 169 67SwedenSWE
- Phone+46 87303700
- Websitehttps://xspraypharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cantargia AB | 0.00 | -280.03m | 612.78m | 22.00 | -- | 3.63 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Oncopeptides AB | 35.22m | -249.11m | 614.09m | 57.00 | -- | 6.50 | -- | 17.44 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Gentian Diagnostics ASA | 133.67m | -10.53m | 622.31m | 58.00 | -- | 4.29 | -- | 4.66 | -0.6905 | -0.6905 | 8.76 | 9.51 | 0.7329 | 1.76 | 7.47 | 2,330,224.00 | -5.77 | -10.76 | -6.62 | -11.86 | 50.61 | 41.46 | -7.88 | -26.99 | 4.13 | -- | 0.0817 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Alligator Bioscience AB | 58.11m | -248.59m | 682.24m | 58.00 | -- | 50.02 | -- | 11.74 | -0.5613 | -0.5613 | 0.1205 | 0.018 | 0.4035 | -- | 8.34 | 1,001,845.00 | -172.61 | -73.26 | -399.57 | -91.33 | -- | -- | -427.81 | -811.68 | -- | -- | 0.5759 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Intellego Technologies AB | 186.49m | 59.61m | 772.13m | 68.00 | 12.39 | 5.11 | 12.23 | 4.14 | 2.36 | 2.36 | 7.43 | 5.74 | 0.8841 | 3.26 | 3.69 | 2,742,544.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 1.97 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| BioPorto A/S | 48.41m | -88.08m | 772.97m | 31.00 | -- | 8.22 | -- | 15.97 | -0.1605 | -0.1605 | 0.0883 | 0.1585 | 0.312 | 3.40 | 11.96 | 998,645.20 | -56.77 | -71.10 | -79.27 | -96.55 | 65.19 | 63.38 | -181.95 | -239.22 | 3.09 | -1,718.97 | 0.1076 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Nightingale Health Oyj | 42.61m | -210.60m | 819.00m | 81.00 | -- | 1.20 | -- | 19.22 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Moberg Pharma AB (publ) | 0.00 | -21.09m | 969.83m | -- | -- | 1.56 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -179.67m | 1.01bn | 26.00 | -- | 1.83 | -- | -- | -7.02 | -7.02 | 0.00 | 22.19 | 0.00 | -- | -- | 0.00 | -26.60 | -18.38 | -28.03 | -19.26 | -- | -- | -- | -- | 4.36 | -- | 0.0504 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vistin Pharma ASA | 433.51m | 55.61m | 1.03bn | 77.00 | 18.53 | 3.51 | 14.07 | 2.38 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
| Cereno Scientific AB | 0.00 | -48.11m | 1.08bn | 5.00 | -- | 4.16 | -- | -- | -0.241 | -0.241 | 0.00 | 0.9258 | 0.00 | -- | -- | 0.00 | -19.22 | -16.81 | -20.75 | -18.26 | -- | -- | -- | -- | -- | -12.92 | 0.1734 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Diamyd Medical AB | 282.00k | -120.18m | 1.08bn | 26.00 | -- | 5.60 | -- | 3,841.28 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| SyntheticMR AB (publ) | 89.21m | 10.01m | 1.14bn | 37.00 | 112.07 | 9.79 | 70.27 | 12.80 | 0.2445 | 0.2445 | 2.17 | 2.80 | 0.6599 | -- | 1.61 | 2,411,162.00 | 7.41 | 7.19 | 8.89 | 8.85 | 105.78 | 106.74 | 11.22 | 9.08 | -- | 14.13 | 0.0107 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 26.79 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -123.07m | 1.15bn | 8.00 | -- | 3.89 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| Arcticzymes Technologies ASA | 117.63m | 18.52m | 1.30bn | 61.00 | 69.97 | 4.27 | 52.48 | 11.08 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
Data as of May 02 2024. Currency figures normalised to XSpray Pharma AB (publ)'s reporting currency: Swedish Krona SEK
15.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 28 Jun 2023 | 2.00m | 6.39% |
| Teknik Innovation Norden Fonder ABas of 30 Jun 2021 | 843.21k | 2.70% |
| Tredje AP-fondenas of 28 Jun 2023 | 800.00k | 2.56% |
| Andra AP-fondenas of 28 Jun 2023 | 622.32k | 1.99% |
| C Worldwide Asset Management Fondsm�glerselskab A/S (Sweden)as of 31 Dec 2023 | 231.20k | 0.74% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 189.54k | 0.61% |
| SEB Investment Management ABas of 28 Mar 2024 | 143.31k | 0.46% |
| Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 100.61k | 0.32% |
| Skandia Investment Management ABas of 29 Feb 2024 | 18.51k | 0.06% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 11.84k | 0.04% |
More ▼
Data from 30 Jun 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
